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SUMMARY
The tuberculosis (TB) bacillus, Mycobacterium tuberculosis (Mtb), and HIV-1 act synergistically; 
however, the mechanisms by which Mtb exacerbates HIV-1 pathogenesis are not well known. 
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Using in vitro and ex vivo cell culture systems, we show that human M(IL-10) anti-inflammatory 
macrophages, present in TB-associated microenvironments, produce high levels of HIV-1. In vivo, 
M(IL-10) macrophages are expanded in lungs of co-infected non-human primates, which 
correlates with disease severity. Further, HIV-1/Mtb co-infected patients display an accumulation 
of M(IL-10) macrophage markers (soluble CD163 and MerTK). These M(IL-10) macrophages 
form direct cell-to-cell bridges, which we identified as tunneling nanotubes (TNTs) involved in 
viral transfer. TNT formation requires the IL-10/STAT3 signaling pathway, and targeted inhibition 
of TNTs substantially reduces the enhancement of HIV-1 cell-to-cell transfer and overproduction 
in M(IL-10) macrophages. Our study reveals that TNTs facilitate viral transfer and amplification, 
thereby promoting TNT formation as a mechanism to be explored in TB/AIDS potential 
therapeutics.
Keywords
AIDS; HIV-1; Tuberculosis; Mycobacterium tuberculosis; Co-infection; Macrophage; Monocyte; 
IL-10; STAT3; Viral spread; Tunneling nanotubes; Biomarker
INTRODUCTION
Worldwide, individuals co-infected with Mycobacterium tuberculosis (Mtb), the agent of 
tuberculosis (TB), and the AIDS virus, HIV-1, pose particular clinical challenges not only 
because a significant proportion of co-infected patients remain sputum smear-negative, 
hampering TB diagnosis, but also because HIV-1 infection makes these individuals more 
prone to TB reactivation (WHO TB 2016, UNAIDS Report 2016)(Getahun et al., 2007). At 
the heart of this problem is the synergy between HIV-1 and Mtb which interferes with 
treatment and promotes the pathogenesis of both pathogens (Diedrich and Flynn, 2011; 
Diedrich et al., 2016). On the one hand, CD4+ T cell decay and other mechanisms induced 
by HIV-1 are a leading cause for reactivation of latent TB and progression to active TB 
disease in AIDS patients (Bell and Noursadeghi, 2018; Tomlinson et al., 2013). On the other 
hand, clinical and epidemiological data clearly identify TB as a risk factor amplifying 
HIV-1-associated morbidity and mortality (Toossi, 2003). However, the mechanisms by 
which Mtb exacerbates HIV-1 infection require further investigation (Charles and Shellito, 
2016; Esmail et al., 2018; Toossi, 2003) (Bell and Noursadeghi, 2018). Addressing this issue 
should help in developing strategies for the attenuation of viral activation in co-infected 
subjects and for a better control of the AIDS epidemic (Diedrich and Flynn, 2011).
Lung macrophages are the primary host cells for Mtb (O’Garra et al., 2013; Russell et al., 
2010). While CD4+ T cells are the major target cells for HIV-1, macrophages, including 
those in the lungs, are also infected by HIV-1 in humans (Bell and Noursadeghi, 2018; 
Cribbs et al., 2015) and by simian immunodeficiency virus (SIV) in experimentally infected 
non-human primates (NHPs) (Avalos et al., 2016). Recent data indicate that macrophages 
play an important role in HIV-1 pathogenesis (Honeycutt et al., 2017; Honeycutt et al., 2016; 
Sattentau and Stevenson, 2016) and may also be involved in HIV-1/Mtb co-infection (Khan 
and Divangahi, 2018; Kuroda et al., 2018). In HIV-1-infected individuals with active TB, for 
example, macrophages from the lungs and pleural effusions (PE) exhibit high levels of 
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HIV-1 infection (Lawn et al., 2001; Toossi, 2003). Furthermore, Mtb increases the level of 
HIV-1 infection either in vitro in monocyte-derived macrophages or ex vivo in lung 
macrophages obtained from patients with HIV-1 (Mancino et al., 1997; Toossi et al., 1997). 
It is presently unclear how a TB-associated microenvironment renders macrophage more 
susceptible to HIV-1.
Macrophages display considerable heterogeneity in tissues (Gordon et al., 2014). The broad 
spectrum of pro- (M1) and anti-inflammatory (M2) activation programs are a manifestion of 
the different levels of response to HIV-1 and Mtb infections (Cassol et al., 2009; Lugo-
Villarino et al., 2011). We have shown that active TB skews human monocyte differentiation 
towards M2-like macrophages, distinguished by a CD16+CD163+MerTK+ phenotype, as 
well as by increased immunomodulatory activity and Mtb permissivity (Lastrucci et al., 
2015). This phenotype is dependent on the IL-10/STAT3 signaling axis and is closely related 
to the so-called “M(IL-10)” activation program (Murray et al., 2014). We further reported 
that the abundance of M(IL-10) cells correlates with TB severity in patients and NHPs 
(Lastrucci et al., 2015). Herein, we investigated whether the TB-induced M(IL-10) 
macrophage activation program also plays a role in promoting HIV-1 infection in co-infected 
individuals.
RESULTS
TB-associated microenvironments increase HIV-1 infection in human macrophages
To determine whether HIV-1 replication is modulated in TB-induced M(IL-10) 
macrophages, we employed our previously described in vitro model (23), which uses 
conditioned medium from either mock-infected macrophages (CmCTR) or Mtb-infected 
macrophages (CmMTB). CmMTB triggered primary human monocytes to differentiate into 
M(IL-10) macrophages, which activated STAT3, as well as acquiring a 
CD16+CD163+MerTK+PD-L1+ receptor signature, similar to differentiated M(IL-10) 
macrophages observed in vivo (Figure S1 and (23)). When macrophages treated with either 
CmCTR or CmMTB were then infected with HIV-1 ADA (Figure 1A) or NLAd8 strain 
(data not shown) (Raynaud-Messina et al., 2018), we observed a substantial increase in viral 
replication, as measured by the level of the viral protein p24 in culture supernatants, only in 
the CmMTB-treated M(IL-10) macrophages (Figures 1B, S2A). In addition, the number of 
HIV-1 infected cells increased by 3-fold, as measured by the expression of the HIV-1 Gag 
protein (Figure 1C–D). The M(IL-10) receptor signature was maintained upon HIV1 
infection (Figure S1). HIV-1 infection of macrophages enhanced their migration capacity in 
dense 3-dimensional matrices, together with their fusion potential, forming multinucleated 
giant cells (MGCs) (Orenstein, 2000; Verollet et al., 2015a; Verollet et al., 2010). We found 
that these properties, known to contribute to viral dissemination (Verollet et al., 2015a; 
Verollet et al., 2015b), were further amplified specifically in M(IL-10) macrophages infected 
with HIV-1 (Figures S2B–E).
Pleural effusion (PE) fluid from TB patients (PE-TB) was used as an ex vivo TB-associated 
microenvironment model (Genoula et al., 2018). PE is observed in up to 30% of TB patients 
and results from infection-induced local inflammation and recruitment of leukocytes into the 
pleural space (Vorster et al., 2015). In co-infected patients, the formation of PE is more 
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common than in TB patients and PE contains high viral titers, compared to serum from the 
same patient (Collins et al., 2002; Toossi, 2003). Unlike control PE obtained from non-TB 
patients (PE-nonTB), differentiation of macrophages in the presence of PE-TB (Table S1 
and Figure 1A) yielded the M(IL-10) phenotype (Figure S3A–B), similar to macrophages 
isolated from PE-TB (Lastrucci et al., 2015). This M(IL-10) phenotype also correlated with 
the high level of soluble IL-10 contained in PE-TB compared to PE-nonTB (Figure S3C). 
We found that cell treatment with PE-TB increased the production of HIV-1 by 6-fold and 
increased the number of infected macrophages and MGCs (Figures 1E–G, S3D).
Collectively, using CmMTB- and PE-TB-conditioned macrophages as model systems, we 
show that HIV-1 production by M(IL-10) macrophages is enhanced in a TB-associated 
microenvironment.
M(IL-10) cells accumulate in co-infected non-human primates and patients
To investigate M(IL-10) cells in HIV-1-Mtb co-infections, we compared, by using CD163 
and pSTAT3 staining (Lastrucci et al., 2015), the number of M(IL-10) macrophages in 
pulmonary samples from NHPs which had been: (i) co-infected with Mtb (active or latent 
TB) and simian immunodeficiency virus (SIV); (ii) mono-infected with Mtb (active or latent 
TB); (iii) mono-infected with SIV (Cai et al., 2015; Kuroda et al., 2018); or (iv) uninfected 
(Tables S2 and S3). Histological staining revealed abundant CD163+ and nuclear pSTAT3+ 
cells in co-infected NHPs (Figure 2A–B). While the detection of pSTAT3 is not specific to 
macrophages, double staining analysis demonstrated that most CD163+ alveolar 
macrophages were also positive for nuclear pSTAT3 (Figure 2C). The increased abundance 
of CD163+ and pSTAT3+ cells was correlated with the severity of lung histopathology 
(Table S3) and the gross pathological status of the animals, as analyzed in 30 organs (Figure 
2D–E).
We have previously shown that CD14+CD16+ circulating monocytes have a predisposition 
to differentiate into M(IL-10) macrophages in patients with active TB (Lastrucci et al., 
2015). Here, we confirmed that CD14+CD16+ monocytes are expanded in the peripheral 
blood of TB, HIV-1, and co-infected patients, compared to healthy subjects (Balboa et al., 
2011; Ellery et al., 2007; Ziegler-Heitbrock, 2007) (Table S1 and Figure S4A). We examined 
two cell surface markers characteristic of the M(IL-10) phenotype, which are selectively 
expressed in the monocytic lineage, CD163 and MerTK, and which are both subjected to 
inflammation-driven shedding (Fabriek et al., 2005; Sather et al., 2007). We found that the 
soluble forms of these receptors (sCD163 and sMer), but not their membrane-bound forms, 
were substantially increased in co-infected patients when compared to mono-infected 
patients and healthy subjects (Figure 3). The amount of these soluble factors correlated with 
one another (Figure S4B). Receiver Operating Characteristic (ROC) curve analyses for 
plasma concentration of sCD163 and sMer (Figure S4C–D) suggested both molecules may 
be useful biomarkers for co-infection.
Our findings reveal the extent of the in vivo expansion of TB-induced M(IL-10) cell 
populations in co-infected individuals. They also identify potential biomarkers for diagnosis 
and monitoring TB in co-infected patients.
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TB-associated microenvironments enhance tunneling nanotube formation
TB-associated microenvironments could increase the level of HIV-1 in M(IL-10) 
macrophages by modulating viral: (i) entry; (ii) replication; (iii) clearance; (iv) infectivity of 
the produced virions; and/or (v) cell-to-cell transmission. We tested each of these 
possibilities in turn. Although cell-surface expression of the HIV-1 entry receptors CD4, 
CCR5 and CXCR4 was increased in CmMTB-treated cells compared to control cells (Figure 
4A), virus entry was unchanged in these cells, as shown using the BlaM-Vpr fusion assay 
(Cavrois et al., 2002) (Figure 4B). The expression level of several host factors known to be 
involved in HIV-1 replication (CEBP-β) or restriction (IFITM proteins and SAMHD1) was 
not modified by CmMTB (Figure 4C–F). As autophagy represents a viral clearance 
mechanism known to be inhibited by HIV-1 or Mtb infection in macrophages (Espert et al., 
2015), we measured the autophagic flux and found it to be similar between CmMTB- and 
CmCTR-treated cells (Figure 4G). Furthermore, the infectivity of viruses produced in 
CmMTB conditions was comparable to those produced in CmCTR-treated cells, (7.7 ± 2.1% 
of p24-positive TZM-bl (Verollet et al., 2015) for CmMTB-treated macrophages vs. 10.3 
± 3.5% for CmCTR-treated cells, n=3; p=0.5066).
Finally, we investigated whether cell-to-cell virus transfer was influenced by TB-associated 
microenvironments. Tunneling nanotube (TNT) formation has been proposed as a 
macrophage-to-macrophage transmission process for host and microbial material (Dupont et 
al., 2018; Eugenin et al., 2009; Hashimoto et al., 2016; Okafo et al., 2017). Importantly, 
TNT formation is triggered by HIV-1 infection of macrophages and it has been associated 
with increase in viral replication (Eugenin et al., 2009; Hashimoto et al., 2016). TNTs are 
long-range membranous F-actin-containing tubes, not in contact with the extracellular 
substrate, which are classified into two types based on their thickness and on whether they 
contain microtubules (Ariazi et al., 2017; Dupont et al., 2018; McCoy-Simandle et al., 2016; 
Onfelt et al., 2006) (Fig 5A). Treatment with CmMTB increased the percentage of cells 
forming both types of TNTs by more than 2-fold (Fig 5A–B), compared to CmCTR-treated 
cells, and HIV-1 infection further amplified this phenomenon (Fig 5B–C).
Using different microscopy approaches, we further characterized macrophage TNTs induced 
by TB-associated microenvironments. The TNTs are: (i) long (up to 200 μm in length) actin-
containing structures connecting two cells, which are above the surface of the substrate 
(Figures 5D, S5A–B, Movies 1–2 and (Dupont et al., 2018); (ii) positive for M-Sec, a 
regulator of TNT formation (Hase et al., 2009) (Figure S5C and Movie 4); and (iii) inhibited 
by cytochalasin D treatment (39 ± 5 % of TNTs in HIV-1-infected CmMTB-treated 
macrophages vs. 6 ± 4 % upon 2 μM Cytochalasin D treatment, n=3; p=0.0003). We also 
observed that CmMTB-induced TNTs contained HIV-1 material and particles (Figure 5E–F 
and Movie 3). Of note, we detected putative TNT-like structures in pulmonary samples from 
NHPs co-infected with Mtb and SIV, as revealed by hematoxylin and eosin staining, or by 
immunohistochemistry targeting CD163-positive macrophages (Figure S5D).
Taken together these data indicate that TB-associated microenvironments do not affect the 
entry, replication, or turnover of HIV-1. Instead, they trigger the formation of TNTs in 
M(IL-10) macrophages which appear to contain HIV-1 particles.
Souriant et al. Page 5
Cell Rep. Author manuscript; available in PMC 2019 September 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
IL-10/STAT3 promotes TNTs and increased viral production in macrophages
We have previously reported that the expansion of M(IL-10) macrophages relies on the 
IL-10/STAT3 signaling pathway (Lastrucci et al., 2015). To study how TB-associated 
microenvironments trigger the formation of TNTs in macrophages, we examined whether 
IL-10/STAT3 signaling was required for the TNT formation and increased HIV-1 production 
induced by TB-associated microenvironments. Recombinant IL-10 triggered M(IL-10) 
macrophage differentiation (Lastrucci et al., 2015) (Figure S6A), increased TNT formation 
(Figure 6A), and recapitulated the TB-driven expansion of HIV-1 infection, as measured by 
p24 release, number of infected cells, (Figure 6B) and formation of MGCs (Figure S6B). 
Depletion of IL10 from CmMTB abolished enhanced TNT formation, the increase in HIV-1 
replication in M(IL-10) cells, and the increase in MGCs (Figures 6C–D, S6C). We examined 
the role of STAT3 activation by pharmacological inhibition with Stattic, which targets the 
STAT3 SH2 domain to prevent association with upstream kinases and abrogates STAT3 
phosphorylation and the associated M(IL-10) phenotype (Lastrucci et al., 2015). Stattic 
treatment inhibited both the CmMTB-driven TNT formation and the increase in HIV-1 
production (Figure 6E,F), along with enhanced cell migration and formation of MGCs 
(Figures S2E, S6D). Of note, treatment of monocytes with others cytokines prior to HIV-1 
infection does not trigger TNT formation significantly, indicating that IL-10 is one of the 
main factor involved in this process (Figure S6E).
Our data demonstrate that TB-associated microenvironments control TNT formation and 
increase HIV-1 infection in macrophages. In addition, they reveal the IL-10/STAT3 axis as a 
signaling pathway involved in TNT formation.
TNTs participate in the high viral production in M(IL-10) macrophages
To determine whether TNT formation is involved in the increased HIV-1 production in 
M(IL-10) macrophages, we used a previously described pharmacological inhibitor of TNT 
formation, TNTi (Hashimoto et al., 2016). We observed that TNTi inhibited the TNT-
mediated transfer of fluorescent material between Di0-stained cells and CellTracker positive 
cells (Fig S7A), without affecting macrophage viability, or F-actin-dependent processes like 
podosome formation and phagocytosis (Maridonneau-Parini, 2014) (Figure S7B–E). In TB-
induced M(IL-10) macrophages infected with HIV-1, TNTi strongly inhibited TNT 
formation (Fig. 7A), significantly diminished HIV-1 overproduction (Figure 7B), and 
reduced MGC formation (Figure S7F).
Unlike in T lymphocytes, the transfer of HIV-1 particles via TNTs has been suggested but 
not formally demonstrated in macrophages (Dupont et al., 2018; Eugenin et al., 2009; 
Hashimoto et al., 2016; Okafo et al., 2017). Thus, we set up a co-culture system between 
M(IL-10) macrophages to assess the transfer of the viral Gag protein from infected donor 
cells to uninfected recipient cells. Uninfected (recipient, CellTracker+, green) and HIV-1-
infected (donor, Gag+, red) macrophages were either co-cultured or separated by a transwell 
membrane that blocks cell-to-cell connections (Figure 7C). Importantly, TNT quantification 
showed that productively infected macrophages preferentially formed TNT (38 ± 6 % of 
TNT formation in Gag+ cells compared to 21 ± 7 % in non-infected CellTracker+ cells, n=5; 
p=0.0003). After 24 hours in co-culture, we observed that donor macrophages were able to 
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transfer the virus to recipient macrophages, which became HIV-1 positive (Figure 7D and 
Movies 5–6). By contrast, the transfer of HIV-1 from donor to recipient macrophages was 
blocked in the transwell cultures (Figure 7E), showing that cell-to-cell contacts are involved 
in this process. In co-culture experiments, TNTi significantly diminished the capacity of 
M(IL-10) macrophages to transfer HIV-1 to recipient cells (Figure 7E), indicating that TNT 
formation is responsible for cell-to-cell viral spread.
These results establish a role for TNTs in spreading the virus between M(IL-10) 
macrophages, uncovering a key cellular mechanism responsible for HIV-1 overproduction in 
the context of TB.
DISCUSSION
TB is the most common co-infection among people living with HIV-1 and is a leading cause 
of AIDS-related deaths. Here, we asked whether TB-associated microenvironments 
influence the control of HIV-1 infection in human macrophages. We report that M(IL-10) 
macrophages (CD163+MerTK+CD16+pSTAT3+), which accumulate in TB patients and can 
be derived in vitro from TB-associated microenvironments, are highly permissive for HIV-1 
production. This exacerbation of HIV-1 infection involves the IL-10/STAT3 signaling axis, 
which controls TNT formation, thus enhancing cell-to-cell transfer of the virus in our 
experimental systems. In vivo, M(IL-10) cells are more abundant in co-infected individuals 
compared to mono-infection settings. We have identified potential biomarkers, sCD163 and 
sMer, in the blood of co-infected patients, which could be used to monitor disease 
progression, as their expression correlates with the severity of the pathology. All things 
considered, our study makes three important contributions to the general understanding of 
how TB exacerbates HIV-1 infection.
First, we show that M(IL-10) macrophages (CD163+pSTAT3+) accumulate in coinfected 
patients and NHPs. In co-infected NHPs, we observe M(IL-10) macrophages in great 
abundance in the lung environment, including the alveolar space and the lung interstitial 
tissue. M(IL-10) macrophage abundance in lungs is correlated with the pathological score of 
the animals, arguing for the physiological and pathological pertinence of these macrophages. 
These macrophages are likely driven by the IL-10/STAT-3 signaling pathway and originate 
from CD14+CD16+ monocytes (Lastrucci et al., 2015), which are increased in the blood of 
patients with active TB, regardless of their HIV-1 infection status (Ziegler-Heitbrock, 2007). 
Monocytes are the only circulating leukocytes known to express membrane-bound CD163 
and MerTK (Fabriek et al., 2005; Sather et al., 2007). As these membrane receptors are 
subjected to inflammation-driven shedding (Fabriek et al., 2005; Sather et al., 2007), their 
soluble form in the blood can be used as a proxy for estimating the abundance of 
CD14+CD16+ monocytes in the circulation. Here, we show that in HIV-1+ patients with 
active TB, the plasma levels of both sCD163 and sMer are significantly higher than those 
found in healthy subjects, HIV-1- or Mtb-infected patients. sCD163 is already described as a 
clinical indicator of monocyte activation in HIV-1 patients (Burdo et al., 2011), as an 
indicator of lesions and accumulation of macrophages in the brain of SIV-infected NHPs 
(Burdo et al., 2010), and as an independent predictor of survival in TB (Knudsen et al., 
2005). Although our findings will need to be expanded in larger cohorts, they nevertheless 
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reveal both sCD163 and sMer as potential tools for the diagnosis and disease monitoring in 
HIV-1/Mtb co-infected patients. Because TB diagnosis in HIV-1-infected individuals remain 
a major clinical challenge (Getahun et al., 2007), sCD163 and sMer may hold great promise 
as biomarkers in these populations.
Second, our study reveals that M(IL-10) macrophages are highly susceptible to HIV-1 
infection. This is accompanied by enhanced MGC formation and protease-dependent 
migration capacity, which could play a role in HIV-1 dissemination (Verollet et al., 2015). 
All these effects are fully dependent on the anti-inflammatory IL-10/STAT3 signaling 
pathway. Most of our work has been done with the ADA virus which is a useful laboratory 
strain that can infect efficiently macrophages with low CD4 levels. However, these viruses 
are rather rare in the blood (Joseph and Swanstrom, 2018). As infected macrophages are 
found in the lungs (Bell and Noursadeghi, 2018; Cribbs et al., 2015), the characterization of 
the types of viruses mainly found in this co-infection sites (lung and pleural cavity) (Collins 
et al., 2002; Nakata et al., 1997; Singh et al., 1999) would be of great interest as we would 
have the opportunity to assess their effect in our model. Other reports also show that Mtb 
infection increases HIV-1 replication in vitro (Diedrich and Flynn, 2011; Goletti et al., 1998; 
Hoshino et al., 2002; Lederman et al., 1994; Zhang et al., 1995). However, unlike our study, 
they show that Mtb induces a pro-inflammatory environment resulting in the auto-activation 
of NF-κB, which ultimately binds the HIV-1 long terminal repeat (LTR) and initiates viral 
transcription in co-infected macrophages (Collins et al., 2002; Goletti et al., 2004; Goletti et 
al., 1998; Hoshino et al., 2002; Lederman et al., 1994; Mancino et al., 1997; Nakata et al., 
1997; Orenstein et al., 1997; Queval et al., 2016; Tanaka et al., 2005; Toossi, 2003; Zhang et 
al., 1995). Based on both these published observations and ours, we propose that TB 
exacerbates HIV-1 pathogenesis in a two-step manner: initially, by activating HIV-1 LTR 
transcription via short-lived pro-inflammatory signals in resident macrophages, and, then, by 
enhancing HIV-1 infection and spread in newly recruited monocytes predisposed towards the 
M(IL-10) phenotype, as a result of the anti-inflammatory signals induced by IL-10. This 
two-step model reconciles previous work done in co-infected cells and the results of our 
study, which is based on inherent susceptibility to HIV-1 infection observed in CD16+ 
monocytes (Ellery et al., 2007) and macrophages derived from these cells (Ancuta et al., 
2006). In light of recent evidence for macrophages as targets for HIV-1 pathogenesis 
(Honeycutt et al., 2017; Honeycutt et al., 2016; Sattentau and Stevenson, 2016), together 
with the renewed appreciation of the importance of IL-10-driven anti-inflammatory program 
in macrophages (Ip et al., 2017), we believe that our in vitro model to generate M(IL-10) 
cells will help further characterize how TB influences viral infection of macrophages, and 
onward viral spread.
Third, based on our findings, we infer that TNT formation are likely a key cellular 
mechanism by which the IL-10/STAT3 signaling axis increases virus spread in human 
macrophages in a TB context. TNTs are transient membrane projections (36, 37, 42) that 
facilitate intercellular communication to allow the transfer of endosomal cargo vesicles, 
calcium fluxes, and pathogens, such as bacteria, viruses and prions (Davis and Sowinski, 
2008; Dupont et al., 2018; Malik and Eugenin, 2016; McCoy-Simandle et al., 2016; Sherer 
and Mothes, 2008). In T cells, transmission of HIV-1 through tunneling nanotubes is 
estimated to be approximately 100–1,000 fold more efficient than through classical cell-free 
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viral infection (Sowinski et al., 2008). In macrophages, HIV-1 induces the formation of TNT 
via the protein Nef (Hashimoto et al., 2016; Xu et al., 2004). We confirmed that Nef is also 
involved in HIV-1-induced TNT formation in a TB-associated microenvironment (data not 
shown). Since the transmission of HIV-1 between macrophages via TNTs had not been 
formally demonstrated, we used here tranwells to separate HIV-1-infected macrophages 
from uninfected macrophages, and we demonstrated that M(IL-10) macrophages are capable 
of transferring HIV1 to non-infected macrophages through a cell-to-cell contact-dependent 
mechanism. While we cannot exclude the contribution of other cell-to-cell contact-
dependent mechanisms of virus spread, such as virological synapse, cell fusion, 
phagocytosis or efferocytosis (Baxter et al., 2014; Bracq et al., 2017; Jolly and Sattentau, 
2004; Karaji and Sattentau, 2017), we clearly show that TNTs play a major role in this 
process. Pharmacological inhibition of TNT formation results in both reduced capacity of 
M(IL-10) macrophages to transfer viral particles and a substantial decrease of HIV-1 
production. TNTs have been observed in several cell types and their formation is stimulated 
by different factors, including lipopolysaccharide (LPS) and IFN-γ, pathogens and oxidative 
stress; yet the signaling pathway(s) involved in TNT formation have not been identified 
(Ariazi et al., 2017; Dupont et al., 2018; Malik and Eugenin, 2016; Zhang, 2011). We reveal 
the IL-10/STAT3-axis as the main signaling pathway responsible for TNT formation 
between macrophages, providing an important contribution to this emerging field and paving 
the way for further elucidating the biology of TNTs. It would be interesting to find out 
whether TNTs could also form between M(IL-10) macrophages and other cell types, such as 
T or B cells, to transfer HIV-1 and/or viral material (Xu et al., 2009), which could participate 
in HIV-1 dissemination and pathogenesis within the co-infection context. Finally, whether 
TNTs are involved in MGC formation during HIV-1 infection of macrophages is suggested 
by a correlation between TNT formation and the number of MGC that are formed (r2=0.7 to 
0.9). Another aspect that needs further improvement is the in vivo relevance of TNTs. 
Despite evidence for material transfer via TNT-like structures in vivo (Naphade et al., 2015; 
Rocca et al., 2017), the current lack of a specific TNT marker prevents the formal 
demonstration of existence of TNT in vivo. In pulmonary tissue lesions of co-infected 
NHPs, we observed TNT-like structures between CD163+ macrophages, suggesting that 
cell-to-cell transfer of HIV-1 via TNTs could also occur in vivo. Indeed, M(IL-10) 
macrophages are in close proximity to each other, particularly in the lungs of co-infected 
NHPs, a parameter that is critical for TNT formation and viral transmission. Taken together 
our results, we propose that enhanced TNT formation induced by TB-associated 
microenvironments in M(IL-10) macrophages favors HIV-1 cell-to-cell transmission and 
consequently, could play a key role in the high HIV-1 levels usually observed at anatomical 
sites of co-infection (Toossi, 2003).
In conclusion, this study highlights the importance of TB-associated microenvironments in 
shaping the response of macrophages to HIV-1 infection. Our results are highly relevant to 
the investigation of the role of macrophages in the pathogenesis of Mtb/HIV-1 co-infection, 
cell signaling pathways involved in TNT formation, and the identification of potential 
biomarkers to monitor disease progression. Future research will reveal whether HIV-1 
production and spread through TB-driven TNT formation occurs among M(IL-10) 
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macrophages only, or also affects macrophage-to-T cell viral transmission (Groot et al., 
2008) and whether TNT can be considered as a therapeutic target in co-infected patients.
EXPERIMENTAL PROCEDURES
Experimental models, study approval and subject details for human subjects and NHP 
samples, bacteria and viruses are described in star METHODS. Methods details are also 
available in star METHODS.
STAR METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by 
the Lead Contact, Geanncarlo Lugo-Vilarino (lugo@ipbs.fr). Sharing of antibodies and other 
reagents with academic researchers may require UBMTA agreements.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects—Monocytes from healthy subjects (HS) were provided by 
Etablissement Français du Sang, Toulouse, France, under contract 21/PLER/TOU/
IPBS01/20130042. According to articles L12434 and R124361 of the French Public Health 
Code, the contract was approved by the French Ministry of Science and Technology 
(agreement number AC 2009921). Written informed consents were obtained from the donors 
before sample collection. The sex of HS is unknown.
Tuberculous (TB) patients from the División de Tisioneumonología at the Instituto de 
Tisioneumonología Vaccarezza-University of Buenos Aires, Argentina and co-infected 
TB/HIV patients from the Division de SIDA at the Hospital F.J Muñiz, from 2015 to 2016, 
were diagnosed by the presence of recent clinical respiratory symptoms, abnormal chest 
radiography and positive sputum smear test for acid-fast bacilli. The research was carried 
out in accordance with the Declaration of Helsinki (2013) of the World Medical Association, 
and was approved by the Ethics Committees of the institutes mentioned above (protocol 
numbers: NIN-1671–12 and proceedings 37/38). Written informed consent was obtained 
before sample collection. Exclusion criteria included the presence of concurrent infectious 
diseases or non-infectious conditions (cancer, diabetes, or steroid therapy). Blood samples 
were collected at 3 to 10 days after start of TB treatment. The diagnosis of tuberculous 
pleurisy was based on a positive Ziehl–Nielsen stain or Lowestein–Jensen culture from 
pleural effusion (PE) and/or histopathology of pleural biopsy, and was further confirmed by 
an Mycobacterium tuberculosis-induced IFN-γ response and an ADA-positive test (Light, 
2010). Effusions were classified as exudates according to Light et al. criteria (Light, 2010). 
PE and peripheral blood (PB) samples were obtained as described previously (Schierloh et 
al., 2007). PB samples from healthy subject (HS) were provided by the Blood Transfusion 
Service, Hospital Fernandez, Buenos Aires (agreement number CEIANM-52-5-2012). All 
HS had received BCG vaccination in childhood and their tuberculin-test status (TTS) was 
unknown. Clinical features and sex of the experimental groups are summarized in Table S1.
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Strategy for randomization and/or stratification. Blood samples from enrolled patients were 
classified in 3 groups of individuals: 1) TB patients with abnormal chest radiography and 
positive sputum smear test for acid-fast bacilli, who received less than one week of anti-TB 
therapy (TB); 2) HIV-1 infected patients with active TB, who received less than one week of 
anti-TB therapy (HIV/TB); and 3) Bacillus Calmette-Guerin-vaccinated healthy donors 
(HS). Pleural effusions samples from enrolled patients were classified in 2 groups of 
individuals: 1) TB pleurisy based on a positive Ziehl–Nielsen stain or Lowestein–Jensen 
culture from PE and/or histopathology of pleural biopsy, and confirmed by an Mtb-induced 
IFN-γ response and an adenosine deaminase-positive test; and 2) no-TB pleurisy including 
the following etiologies: malignant effusions (mesothelioma, lung carcinoma or metastatic 
patients), parapneumonic effusions and heart failure associated effusions.
Inclusion and Exclusion criteria for blood samples. Inclusion: person >21 years old 
diagnosed with TB (clinical or laboratory criteria) having HIV+ serology (HIV/TB) or not 
and who consent to participate. Exclusion: the presence of concurrent infectious diseases, 
except HIV, or non-infectious conditions (cancer, diabetes, or steroid therapy) and patients 
who do not provide consent.
Inclusion and Exclusion criteria for pleural effusion samples. Inclusion: person >21 years 
old having a pleural effusion requiring drainage by therapeutic thoracentesis and who 
consent to participate. Exclusion: the presence of empyema, pleural effusion that does not 
require therapeutic drainage and patients who do not provide consent.
The GPower software was used for sample-size estimation and statistics. No replicates and 
no blinding were done.
Non-Human Primate samples—All animal procedures were approved by the 
Institutional Animal Care and Use Committee of Tulane University, New Orleans, LA, and 
were performed in strict accordance with NIH guidelines. The twenty adult rhesus macaques 
used in this study (Table S2) were bred and housed at Tulane National Primate Research 
Center (TNPRC). The sex of animals is specified in Table S2. All macaques were infected as 
previously described (Foreman et al., 2016; Mehra et al., 2011). Briefly, macaques were 
aerosol-exposed to a low dose (25 CFU implanted) of Mtb CDC1551 and a subset of the 
macaques were also exposed 9 weeks later to 300 TCID50 of SIVmac239 administrated 
intravenously in 1mL saline. The control subset received an equal volume of saline 
intravenously. Criteria for killing included presentation of four or more of the following 
conditions: (i) body temperatures consistently greater than 2°F above preinfection values for 
3 or more weeks in a row; (ii) 15% or more loss in body weight; (iii) serum CRP values 
higher than 10 mg/mL for 3 or more consecutive weeks, CRP being a marker for systemic 
inflammation that exhibits a high degree of correlation with active TB in macaques (Kaushal 
et al., 2012; Mehra et al., 2011); (iv) CXR values higher than 2 on a scale of 0–4; (v) 
respiratory discomfort leading to vocalization; (vi) significant or complete loss of appetite; 
and (vii) detectable bacilli in BAL samples.
Bacteria—Mtb H37Rv strain was grown in 7H9 media at 37°C, as described (Lastrucci et 
al., 2015). Exponentially growing Mtb was centrifuged (460g) and resuspended in PBS 
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(MgCl2, CaCl2 free, Gibco). Clumps were dissociated by 20 passages through a 26-G needle 
then resuspended in RPMI-1640 containing 10% FBS. Bacterial concentration was 
determined by measuring OD600.
Viruses—Proviral infectious clones of the macrophage-tropic HIV-1 isolate ADA (Verollet 
et al., 2015a) was kindly provided by Serge Benichou (Institut Cochin, Paris, France). 
Virions were produced by transient transfection of 293T cells with proviral plasmids, as 
previously described (Verollet et al., 2015a). HEK 293 T cells (the sex of original cells is 
unknown) were maintained in DMEM, 20% FBS, 5% CO2. HIV-1 p24 antigen 
concentration of viral stocks was assessed by an home-made ELISA. HIV-1 infectious units 
were quantified, as reported (Verollet et al., 2015a) using TZM-bl cells. TZM-bl cells are 
Hela cell lines (female origin) that were obtained through NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme 
Inc). TZM-bl In some experiments, we used Betalactamase (BlaM)-Vpr-containing ADA 
virus and NLAD8-VSVG pseudotyped viruses and HIV-1 ADA Gag-iGFP strain (see Key 
Resource Table).
Preparation of human monocytes and monocyte-derived macrophages—
Monocytes from healthy subjects (HS) were isolated and differentiated into macrophages as 
previously described (Balboa et al., 2011; Lastrucci et al., 2015; Verollet et al., 2015a). 
Briefly, purified CD14+ monocytes from HS were differentiated for 5–7 days in RPMI-1640 
medium (GIBCO), 10% Fetal Bovine Serum (FBS, Sigma-Aldrich) and human M-CSF 
(Peprotech) at 20 ng/mL. Differentiated macrophages were used as the cellular source to 
prepare the CmMTB after infection with Mtb. The cell medium was renewed every 3 or 4 
days. For the human samples of peripheral blood and pleural effusion (PE) from nonTB, TB 
and HIV-1/TB patients and HS, mononuclear cells were isolated by Ficoll Hypaque gradient 
centrifugation (Pharmacia, Uppsala, Sweden), as described previously (Balboa et al., 2011; 
Lastrucci et al., 2015). Isolated monocytes from patients were allowed to adhere to 24-well 
plates, at 5x105 cells/well for 1 h at 37°C in warm RPMI-1640 medium. The medium was 
then supplemented to a final concentration of 10% FBS and human recombinant M-CSF at 
10 ng/mL. Flow cytometry analysis was performed in mononuclear cells, gating within the 
CD14+ population.
METHODS DETAILS
Chemicals—When stated, monocytes (day 0) are treated with STAT3 activation inhibitor 
Stattic (1μM, kindly provided by Fabienne Meggetto from CRCT, INSERM Toulouse). In 
some conditions, monocytes (day 0) were treated with an inhibitor of TNT formation (TNTi, 
20μM, Pharmeks), which was renewed after HIV-1 infection. In some experiments, 
macrophages were treated with Cytochalasin D (Sigma-Aldrich) at 2 μM. DMSO alone was 
used as vehicle control.
Preparation of conditioned media and cytokine depletion—The preparation of the 
conditioned medium of Mtb-infected macrophages (CmMTB) has been reported previously 
(Lastrucci et al., 2015). Briefly, macrophages were infected with Mtb H37Rv at a MOI of 3. 
The conditioned control medium (CmCTR) was obtained from uninfected macrophages. 
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After incubation at 37°C for 18h, culture media were collected, sterilized by filtration 
(0.2μm pores) and aliquots were stored at −80°C. For cytokine depletion experiments, 
CmCTR or CmMTB were incubated with 10 μg/mL of control IgG or neutralizing IL-10 
antibody (JES3-19F1, Biolegend) for 1h at 4°C. Afterwards, 50 μg/mL of 50% slurry 
Protein G agarose beads (EMD Millipore) were added and incubated for 1h at 4°C. 
Conditioned media were centrifuged (300g) to remove antibody-bead complexes and then 
filtered (0.2 μm pores) before use. The depletion was controlled by ELISA.
Conditioning of monocytes with the secretome of Mtb-infected macrophages 
or pleural effusions from TB patients—Freshly isolated CD14+ monocytes from HS 
were allowed to adhere in the absence of serum (4×105cells/24-well in 50μl or 2×106 
cells/6-well in 1.5ml). After 1h of culture, CmMTB or CmCTR supplemented with 20 
ng/mL M-CSF and 20% FBS were added to the cells (vol/vol). For experiments with PE, 
samples were collected in heparin tubes and centrifuged at 300 g for 10 minutes at room 
temperature without brake. The cell-free supernatant was transferred into new plastic tubes, 
further centrifuged at 12000 g for 10 minutes and aliquots were stored at −80°C. After 
having the diagnosis of the PE, pools were prepared by mixing same amounts of individual 
PE associated to a specific etiology. The pools were de-complemented at 56°C for 30 
minutes, and filtered by 0.22 μm in order to remove any remaining debris or residual 
bacteria. Particularly, we studied 21 patients with PE that were divided according their 
etiology. First group had 8 patients with tuberculous PE (PE-TB), second group had 8 
patients with parapneumonic PE (PE-NPI), and third group had 5 patients with transudates 
secondary to heart failure (PE-HF). PE-TB or PE-nonTB (PE-NPI and PE-HF) 
supplemented with 40ng/mL M-CSF and 40% FBS were added to the cells (25% vol/vol). 
Cells were then cultured for 3 days. Monocytes were also conditioned in presence of 10 
ng/mL M-CSF and 10 ng/mL recombinant human Interleukin-10 (IL-10) (PeproTech). Cell-
surface expression of macrophage activation markers was measured by flow cytometry using 
standard procedures detailed in supplemental information.
HIV-1 infection of cells—Cells were infected with HIV-1 ADA strain at day 3 of culture 
at MOI 0.1. HIV-1 infection and replication were assessed 10 days post-infection by 
measuring p24-positive cells by immunostaining and the level of p24 released in culture 
media by ELISA.
Blam-Vpr fusion assay—Experiments were carried out as described previously (Garcia-
Perez et al., 2015). Briefly, monocytes adhered on glass coverslips were conditioned for 3 
days with CmMTB or CmCTR medium and then collected with cell dissociation buffer 
(Thermo Fisher Scientific). Then, 1.5 × 105 cells were incubated for 3 h at 37°C with 100 ng 
p24 of a Betalactamase (BlaM)-vpr-containing ADA virus. Infected cells were next 
incubated for 2 h with the CCF2/AM dye according to the manufacturer’s instructions 
(Invitrogen). After washing, cells were fixed in 2% paraformaldehyde. Enzymatic cleavage 
of CCF2 by BlaM, which causes a blue-shift in the CCF2 fluorescence emission spectrum, 
was measured by flow cytometry (FACSCanto, BD Biosciences).
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Flow cytometry—Staining of conditioned monocytes-to-macrophage population was 
performed as previously described (Lastrucci et al., 2015). Adherent cells were harvested 
using Cell Dissociation Buffer (Life Technologies), centrifuged for 5 min at 340xg, 
incubated in staining buffer (PBS, 2mM EDTA, 0.5% FBS) with a 1:100 dilution of Human 
TruStain FcX (Biolegend) for 5 minutes at room temperature. Cells were then stained in cold 
staining buffer for 25 min with fluorophore-conjugated antibodies (See Table S4) and in 
parallel, with the corresponding isotype control antibody using a general dilution of 1:400. 
After staining, the cells were washed with cold staining buffer, centrifuged for 5 min at 340g 
at 4°C (twice), and analyzed by flow cytometry using LSR-II flow cytometer (BD 
Biosciences) and the associated BD FACSDiva software. Data was then analyzed using the 
FlowJo 7.6.5 software (TreeStar). The monocyte-to-macrophage population was first gated 
according to its Forward Scatter (FSC) and Size Scatter (SSC) properties before singlet 
selection and analysis of the percentage of positive cells and the median fluorescence 
intensity (MFI) for each staining.
Cells from nonTB, TB and HIV/TB patients and related controls from HS (2 × 105 cells) 
were labeled as described above and acquired in a FACSAria II cytometer (BD Biosciences) 
and analyzed using FCS Express V3 software (De Novo Software, Los Angeles, CA, USA).
Immunofluorescence microscopy—Cells were fixed with PFA 3.7%, Sucrose 30mM 
in PBS. Stainings were performed as described (Verollet et al., 2015a). Briefly, cells were 
permeabilized with Triton X-100 0,3% for 10 minutes, and saturated with PBS BSA 1% for 
30 minutes. Cells were incubated with anti-Gag KC57 antibody (1:100, Beckman Coulter) 
in PBS BSA 1% for 1 hour, washed and then incubated with Alexa Fluor 555 Goat anti-
Mouse IgG secondary antibody (1:1000, Cell Signaling Technology), Alexa Fluor 488 
Phalloidin (1:500, Thermo Fisher Scientific) and DAPI (500 ng/mL, Sigma Aldrich) in PBS 
BSA 1% for 30 minutes. Coverslips were mounted on a glass slide using Fluorescence 
Mounting Medium (Dako). Slides were visualized with a Leica DM-RB fluorescence 
microscope or a FV1000 confocal microscope (Olympus). For deconvolution images shown 
in Figures 5E, S5A and C, macrophages were imaged over nine planes at 100 nm intervals 
with a 100x/1.49 Nikon objective mounted on a Nikon Eclipse Ti-E and an Hamamatsu Orca 
flash 4.0 LT sCMOS. All images were deconvolved with Huygens Professional version 
16.10 (Scientific Volume Imaging, The Netherlands), using the CMLE algorithm, with SNR:
20 and 40 iterations.
For the deconvolution image shown in Figure 7D, imaging was performed using a dragonfly 
multimodal imaging platform in three-dimensional fast confocal mode using a 63x/1.47 
objective and a Zyla 4.2 PLUS sCMOS camera (Andor).
Tunneling nanotubes (TNTs) were detected and counted using Phalloidin and microtubules 
staining. We quantified both thick and thin nanotubes: thin membrane nanotubes contained 
only F-actin, whereas thick TNTs contained both F-actin and microtubules.
As HIV-1 infection of macrophages makes them fuse into MGC (Orenstein, 2001; Verollet 
et al., 2010), the number of infected cells largely underestimates the rate of infection. Thus, 
to better reflect the rate of infection, we quantified HIV infection index (HIV-stained area 
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divided by total cell area × 100), percentage of nuclei in multinucleated cells and percentage 
of multinucleated cells. These parameters were assessed by using semi-automatic 
quantification with home-made Image J macros, allowing the study of more than 5,000 cells 
per condition in at least five independent donors.
HIV-1 and DiO transfer monitoring—Freshly isolated CD14+ monocytes from HS were 
allowed to adhere in the absence of serum (2×106 cells/6-well in 1.5ml). After 1h of culture, 
RPMI medium supplemented with 20 ng/mL M-CSF and 20% FBS and 20ng/mL IL-10 
were added to the cells (vol/vol). At day 3, half cells are infected with 120ng p24 of a HIV-1 
NLAD8 strain pseudotyped with a VSVG envelope. The other half cells are stained with 
CellTracker Green CMFDA Dye at day 5 (Thermo Fisher Scientific). Briefly, cells are 
washed with Mg2+/Ca2+-containing PBS and stained for 30 minutes in Mg2+/Ca2+-
containing PBS supplemented with 500 ng/mL CellTracker, then washed with FBS-
containing RPMI medium. HIV+ and CellTracker+ were then detached using accutase and 
co-cultured at a 1:1 ratio. In order to co-culture HIV+ and CellTracker+ cells in conditions 
that allow their physical separation, HIV+ cells were plated on 6.5-mm transwell filters with 
0.4 μm pore polyester membrane insert (Sigma-Aldrich) while CellTracker+ cells were 
plated on coverslips at the bottom of 24-well plates holding the transwell filters. The cells 
therefore shared only the culture medium but were unable to physically contact each other. 
For the cell-free HIV-1 control, CellTracker+ cells were incubated with the supernatant of 
HIV+ cells containing produced virions. After 24 h, cells were fixed, stained and imaged.
For DiO transfer monitoring, cells were stained either with CellTracker Red CMPTX Dye 
(Thermo Fisher Scientific) as described above, or with a lypophylic tracer Vybrant® DiO 
(Thermo Fisher Scientific), according to manufacturer’s instructions. Then, cells were 
detached using accutase, co-cultured at a 1:1 ratio in 8-well Lab-Tek® chambers for 24h and 
imaged.
Scanning electron microscopy—Scanning electron microscopy observations were 
performed as previously described (Lastrucci et al., 2015). Briefly, HIV-1-infected 
macrophages were fixed in 2.5% glutaraldehyde/3,7% PFA/0.1M sodium cacodylate (pH 
7.4), post-fixed in 1% osmium tetraoxide (in 0.2M cacodylate buffer), dehydrated in a series 
of increasing ethanol. Critical point was dried using carbon dioxide in a Leica EMCPD300. 
After coating with gold, cells were examined with a FEI Quanta FEG250 scanning electron 
microscope.
Immunoblot analyses—Total protein lysates were extracted as previously described 
(Lastrucci et al., 2015; Verollet et al., 2015a). Total proteins were separated through SDS-
polyacrylamide gel electrophoresis, transferred and immunoblotted overnight at 4°C with 
indicated primary antibodies (See Key Resource Table). Secondary antibodies were the 
following: Anti-rabbit and anti-mouse IgG, HRP-linked Antibody (Cell Signaling 
Technology). Proteins were visualized with Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare). Chemiluminescence was detected with ChemiDoc 
Touch Imaging System (Bio-Rad Laboratories) and quantified using Image Lab software 
(Bio-Rad Laboratories). For the detection of LC3 autophagy protein, monocytes were 
seeded on 12-well plates at a density of 0.8 × 106 cells by well. After infection and treatment 
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with Bafilomycin A1 (100 nM) or DMSO vehicle control for 2 h, cells were lysed. Proteins 
harvested were subjected to a SDS-polyacrylamide gel electrophoresis, 4–15% gradient 
(Biorad). Blots were blocked with 5% dried milk in PBS, incubated with LC3 primary 
antibody and then with the corresponding horseradish peroxidase-conjugated secondary 
antibody (ThermoScientific). Staining was detected with SuperSignal WestPico 
Chemiluminescent Substrate (ThermoScientific), and immunostained proteins were 
visualized using the ChemidocTouch Imaging System (Biorad). Densitometric LC3-II/actin 
ratios were measured using the Image J software.
3D migration assays—3D migration assays of cells in Matrigel (10–12 mg/mL, BD 
Biosciences) were performed as described (Verollet et al., 2015a) and quantified at 48h. 
Briefly, pictures of cells were taken automatically with a 10X objective at constant intervals 
using the motorized stage of an inverted microscope (Leica DMIRB, Leica Microsystems). 
Cells were counted using Image J software as described previously (Verollet et al., 2015a). 
The number of cells inside the matrix (% of migration measured after 48h of migration) was 
quantified.
Protein quantifications in cell-free fluids by ELISA—Soluble protein concentration 
was measured in cell supernatants by ELISA using kits from BD Bioscience (IL-10) and 
R&D Systems (sCD163 and sMer), according to manufacturer’s instructions.
Cytotoxicity assay—To exclude any impact of cytotoxicity of TNTi used in this study we 
measured lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells 
into the supernatant. LDH release was measured using the Cytotoxicity Detection kit 
(Roche, Mannheim, Germany) according to the manufacturer’s instructions. Monocytes 
were treated with TNTi (20μM) or DMSO as a control for 13 days. Cell-free culture 
supernatants were collected and incubated with LDH assay solution at 25°C for 30 min. The 
optical density values were analyzed at 490 nm by subtracting the reference value at 620 nm.
Phagocytosis assay—IgG-opsonized zymosan was prepared by incubating particles in 
suspension in PBS with human IgG (13 mg/ml, 30 min at 37°C) and washing as described 
(Le Cabec and Maridonneau-Parini, 1994). The number of particles was counted in a 
Malassez chamber. FITC-labeled zymosan particles were then added at a MOI of 5 and 
incubated for 30 minutes at 37°C. Cells were then extensively washed with PBS and fixed in 
3,7% PFA. To exclusively quantify phagocytosis and not binding, extracellular zymosan was 
stained as described (Le Cabec et al., 2000).
Histological analyses—Paraffin embedded tissue samples were sectioned and stained 
with hematoxylin and eosin for histomorphological analysis. Immunohistochemical staining 
was performed on paraffin-embedded tissue sections, using anti-CD163 (10D6, mouse mAb, 
Leica/Novocastra) and anti-pSTAT3 (D3A7 rabbit mAb, Cell Signaling Technology). 
Immunostaining of paraffin sections was preceded by different antigen unmasking methods. 
After incubation with primary antibodies, sections were incubated with biotin-conjugated 
polyclonal anti-mouse or anti-rabbit immunoglobulin antibodies followed by the 
streptavidin-biotin-peroxidase complex (ABC) method (Vector Laboratories) and then were 
counter-stained with hematoxylin. Slides were scanned with the Panoramic 250 Flash II 
Souriant et al. Page 16
Cell Rep. Author manuscript; available in PMC 2019 September 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(3DHISTECH). Virtual slides were automatically quantified for macrophage distribution as 
previously described (Lastrucci et al., 2015; Verollet et al., 2015a). For confocal microscopy, 
samples were stained with primary antibodies as described above and followed by anti-
mouse IgG isotype specific or anti-rabbit IgG antibodies labeled with Alexa488 and 
Alexa555 (Molecular Probes). Samples were mounted with Prolong® Antifade reagent 
(Molecular Probes) and examined using a 60x/1.40N.A. objective of an Olympus FV1000 
confocal microscope.
QUANTIFICATION AND STATISTICAL ANALYSIS
Information on the statistical tests used, and the exact values of n (number of donors) can be 
found in the Figure Legends. All statistical analyses were performed using GraphPad Prism 
6.0 (GraphPad Software Inc.). The statistical tests were chosen according to the following. 
Two-tailed paired or unpaired t-test was applied on data sets with a normal distribution 
(determined using Kolmogorov-Smirnov test), whereas two-tailed Mann-Whitney (unpaired 
test) or Wilcoxon matched-paired signed rank tests were used otherwise. p<0.05 was 
considered as the level of statistical significance (* p≤0.05; ** p≤0.005; *** p≤0.0005; **** 
p≤0.0001).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. (Related to Figure S1, S2, S3). TB-induced microenvironments exacerbate HIV-1 
infection of M(IL-10) macrophages.
(A) Representation of the experimental design of two in vitro models. Briefly, monocytes 
from healthy subjects were treated either with conditioned medium from mock- (CmCTR) 
or Mtb-infected macrophages (CmMTB), or with pleural effusions (PE) from TB (PE-TB) 
or non-TB (PE-nonTB) patients for 3 days. Cells were then infected with HIV-1 ADA strain 
at MOI of 0.1 and kept in culture for at least 10 more days. (B) Vertical scatter plot showing 
p24 concentration from day 13 supernatants of HIV-1 infected macrophages treated with 
CmCTR or CmMTB. (C) Vertical scatter plot showing the infection index of day 13 HIV-1 
infected macrophages treated with CmCTR or CmMTB. Infection index was calculated as 
100 x the ratio of the area covered by Gag+ cells over the total cell area, measured from 
immunofluorescence (IF) images. (D) Representative IF images of day 13 HIV-1 infected 
macrophages treated with CmCTR or CmMTB. HIV-1 Gag (red), F-actin (green), DAPI 
(blue). Scale bar, 500μm. Insets are 4x zooms (lower panels). (E) Vertical scatter plot 
showing p24 concentration from day 13 supernatants of HIV-1 infected macrophages treated 
with PE-TB or PE-nonTB. (F) Vertical scatter plot showing the infection index of day 13 
HIV-1 infected macrophages treated with PE-TB or PE-nonTB. (G) Representative IF 
images of day 13 HIV-1 infected macrophages treated with PE-nonTB or PE-TB. HIV-1 Gag 
(red), F-actin (green), DAPI (blue). Scale bar, 500μm. Insets are 4x zooms (lower panels). 
Each circle within vertical scatter plots represents a single donor. Mean value is represented 
as a dark grey line. In this figure, PE-nonTB are parapneumonic PE. Statistical analyses: 
Two-tailed, Wilcoxon matched-paired signed rank test (B,C), paired t-test (E,F). ** p≤0.005; 
*** p≤0.0005; **** p≤0.0001.
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Figure 2. (Related to Table S2, S3). Accumulation of M(IL-10) macrophages in the lung of co-
infected non-human primates (NHPs) correlates with pathology.
(A)Representative immunohistochemical images illustrate higher number of CD163+ cells 
and pY705-STAT3+ cells in lung biopsies of SIV-Mtb infected NHPs compared to Mtb or 
SIV mono-infected NHPs. Scale bar, 100μm. Insets are 4x zooms. (B) Quantification of the 
number of CD163+ cells (left) and pY705-STAT3+ cells (right) per mm2 of lung tissue of 
healthy (H), SIV-infected, Mtb-infected and SIV-Mtb-co-infected NHPs. (C) 
Immunohistochemistry staining of lung biopsy of SIV-Mtb co-infected NHP showing the 
nuclear localization of pY705-STAT3 (red, center) in CD163 alveolar macrophages (green, 
top). Nuclei are stained using DAPI (blue, bottom). Scale bar, 50 μm. Insets are 1.3x zooms. 
(D) Vertical scatter plot showing the pathological scoring of NHPs used in this study (See 
Table S3). (E) Correlation between CD163+ cells (left) or pY705-STAT3+ cells (right) per 
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mm2 of lung tissue and pathological score in the indicated NHPs. Each symbol within 
vertical scatter plots represents a single animal. Mean value is represented as a dark grey 
line. Statistical analyses: Two-tailed Mann-Whitney (B,D). * p≤0.05; ** p≤0.005; ns, not 
significant.
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Figure 3. (Related to Figure S4 and Table S1). Systemic expansion of the M(IL-10) monocyte 
population in co-infected patients.
(A) Vertical scatter plots showing the median fluorescence intensity (MFI) of cell-surface 
marker CD163 on CD14+ monocytes from peripheral blood of healthy subjects, TB patients 
(TB) and HIV-1/Mtb co-infected patients (HIV/TB). (B) Vertical scatter plots showing the 
amount of sCD163, the cleaved form of CD163 in the serum of healthy subjects, TB, HIV 
and HIV/TB patients. (C) Vertical scatter plots showing the MFI of cell-surface marker 
MerTK on CD14+ monocytes from PB of healthy subjects, TB and HIV/TB patients. (D) 
Vertical scatter plots showing the amount of sMer, the cleaved form of MerTK in the serum 
of healthy subjects, TB, HIV and HIV/TB patients. Each circle within vertical scatter plots 
represents a single donor. Mean value is represented as a dark grey line. Statistical analyses: 
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Two-tailed, Mann-Whitney (A-C), unpaired t-test (D). * p≤0.05; ** p≤0.005; *** p≤0.0005; 
ns, not significant.
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Figure 4. (Related to Figure S5). The TB-driven exacerbation of HIV-1 infection in macrophages 
is not due to modulation in viral entry, HIV-1related activation or restriction factors, or 
autophagy.
(A) Vertical scatter plots showing the Median Fluorescence Intensity (MFI) of cell-surface 
receptors involved in HIV-1 entry (CD4, CCR5, CXCR4) on monocytes differentiated for 3 
days under the presence of CmCTR and CmMTB. Each circle within vertical scatter plots 
represents a single donor. Mean value is represented as a dark grey line. (B) Histogram 
showing the percentage of HIV-1 fusion with CmCTR- (white) or CmMTB (black)-pre-
treated cells, as determined using the Blam-Vpr assay in the presence of entry inhibitor 
Maraviroc (dashed bars). (C) Left: Representative images of Western Blot analysis 
illustrating the expression of IFITM1/2/3 and Actin as loading control. Right: Quantification 
of IFITM1/2/3 expressed as a ratio related to actin of monocytes differentiated for 3 days 
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into macrophages under the presence of CmCTR (white) and CmMTB (black). n = 6 donors. 
(D) Representative images of Western Blot analysis illustrating the expression of SAMHD1 
and its phosphorylated version (pSAMHD1), and Actin as loading control (left). 
Quantification of SAMHD1 (center) pSAMHD1 (right) expressed as a ratio related to actin 
of monocytes differentiated for 3 days into macrophages under the presence of CmCTR and 
CmMTB. n = 11 donors. (E) Representative images of Western Blot analysis illustrating the 
expression of C/EBP-β (LAP), C/EBP-β (LIP), and Actin as loading control (left). 
Quantification of C/EBP-β (LAP, center left) and C/EBP-β (LIP, center right) expressed as 
a ratio related to actin, and LAP expressed as a ratio related to LIP (right), of monocytes 
differentiated for 3 days into macrophages under the presence of CmCTR and CmMTB. n = 
9 donors. LAP is an activator of HIV-1-LTR whereas LIP is a repressor of HIV-1-LTR. (F) 
Representative images of Western Blot analysis illustrating the expression of CUGBP1 and 
Actin as loading control (left). Quantification of CUGBP1 expressed as a ratio related to 
actin (right) of monocytes differentiated for 3 days into macrophages under the presence of 
CmCTR and CmMTB. n = 9 donors. (G) Quantification of LC3-II expression as a ratio to 
actin of monocytes differentiated for 3 days under the presence of CmCTR and CmMTB at 
the indicated time points after 2h treatment with Bafilomycin A1 (BafA1) or DMSO as 
control, as measured by western blot analysis. Uninfected cells at day 3 of the experiment 
(left, n = 6 donors), and HIV-infected cells at 1 (day 4, center, n = 4 donors) and 3 (day 6, 
right, n = 6 donors) days post-infection. Each circle within vertical scatter plots represents a 
single donor. Mean value is represented as a dark grey line. Data in histograms are 
represented as mean ± SD. * p≤0.05; ** p≤0.005; *** p≤0.0005; **** p≤0.0001.
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Figure 5. (Related to Movie 3). TB enhances HIV-1-induced tunneling nanotube (TNT) 
formation.
(A)Representative immunofluorescences image of macrophages interconnected through 
thick (left) and thin (right) TNTs. F-Actin (red), Tubulin (green), DAPI (blue). Scale bar, 20 
μm. The arrows point at the thin TNT without microtubules. (B) Stacked bars showing the 
percentage of cells with thick (grey) and thin (white) TNTs of day 6 uninfected or HIV-1-
infected macrophages treated with CmCTR or CmMTB. Data in histograms are represented 
as mean ± SD. (C) Representative wide field Immunofluorescence (IF) images showing F-
actin staining in day 6 HIV-1 infected macrophages, treated with CmCTR or CmMTB. 
Arrows: thick TNTs; arrowheads: thin TNTs. Scale bar, 20μm. (D) Scanning electron 
microscopy images showing TNTs of day 6 HIV-1 infected macrophages, treated with 
CmMTB. Arrows : thick TNTs ; arrowheads : thin TNTs. Scale bar, 20μm. (E) 
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Deconvolution microscopy images showing HIV-1 Gag intra-TNT distribution in day 6 
HIV-1 infected macrophages, treated with CmMTB. HIV-1 Gag (red), F-actin (green), DAPI 
(blue). Scale bar, 20μm. Insets are 3x zooms. (F) Immunofluorescence (IF) images showing 
viral particles in TNT of day 6 HIV-1-Gag-iGFP infected macrophages previously treated 
with CmMTB. HIV-1-Gag-GFP (green), F-actin (red) and DAPI (blue). Scale bar, 10μm. 
Inset is 4x zoom. Statistical analyses: Two-tailed paired t-test (B). * p≤0.05; ** p≤0.005; 
*** p≤0.0005; **** p≤0.0001; ns, not significant.
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Figure 6. (Related to Figure S2, S6). TB-driven tunneling nanotube (TNT) formation and 
increased of HIV-1 infection are dependent on the IL10/STAT3 axis.
(A)Stacked bars showing the percentage of cells with thick (grey) and thin (white) TNTs of 
day 6 HIV-1 infected macrophages untreated or treated with recombinant IL-10 (10ng/mL). 
(B) Vertical scatter plots showing p24 concentration (left) and infection index (right) of day 
13 HIV-1 infected macrophages untreated or treated with recombinant IL-10 (10ng/mL). (C) 
Stacked bars showing the percentage of cells with thick (grey) and thin (white) TNTs of day 
6 HIV-1 infected macrophages treated with IL-10-depleted (α-IL-10) CmMTB and mock 
depletion controls (α-IgG) of CmCTR and CmMTB. (D) Vertical scatter plots showing p24 
concentration (left) and infection index (right) of day 13 HIV-1 infected macrophages 
treated with IL-10-depleted (α-IL-10) CmMTB and mock depletion controls (α-IgG) of 
CmCTR and CmMTB. (E) Stacked bars showing the percentage of cells with thick (grey) 
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and thin (white) TNTs of day 6 HIV-1 infected macrophages treated with CmCTR, CmMTB 
or CmMTB in the presence of the STAT3 activation inhibitor, Stattic (1μM). (F) Vertical 
scatter plots showing p24 release (left) and infection index (right) of day 13 HIV-1 infected 
macrophages treated with CmCTR, CmMTB or CmMTB in the presence of the STAT3 
activation inhibitor, Stattic (1μM). Statistical analyses: Two-tailed, Wilcoxon matched-paired 
signed rank test (B right, D right, F), paired t-test (A, B left, C, D left, E). * p≤0.05; ** 
p≤0.005; *** p≤0.0005; ns, not significant.
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Figure 7. (Related to Figure S7 and Movies 5 and 6). TB-driven tunneling nanotube (TNT) 
formation is necessary for increased HIV-1 infection.
(A) Stacked bars showing the percentage of cells with thick (grey) and thin (white) TNTs of 
day 6 HIV-1 infected macrophages treated with CmCTR, CmMTB or CmMTB in the 
presence of TNT inhibitor (TNTi, 20μM). (B) Vertical scatter plots showing p24 release 
(left) and infection index (right) of day 13 HIV-1 infected macrophages treated with 
CmCTR, CmMTB or CmMTB in the presence of TNTi. (C) Experimental set-up used for 
the co-culture (also referred to as a transfer assay), transwell and cell-free HIV-1 
experiments. IL-10-treated MDM were either infected with HIV-1 NLAD8-VSVG 
pseudotyped strain at a MOI 5 for 48h (donor cells) or stained with CellTracker (acceptor 
cells). For the co-culture experiment, donor cells were mixed with acceptor cells at a 1:1 
ratio. The transwell assay was designed to separate donor and acceptor cells to investigate 
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the contribution of cell contact to transfer of HIV-1. The experiment was performed as 
described in the co-culture assay, with the exception that acceptor cells were plated in the 
well, and then a transwell filter was placed containing the donor cells. Finally, to assess the 
contribution of cell-free infection in the propagation of HIV-1, the supernatant of donor cells 
(containing the virions produced during 48h of infection) was incubated with acceptor cells. 
To assess the contribution of TNTs in HIV-1 transfer, all 3 experiments were performed in 
the presence or not of TNTi (20μM), and fixed after 24h. The cells were stained for HIV-1 
Gag protein and the percentage of CellTracker+ cells among Gag+ cells was quantified. (D) 
Deconvolution microscopy image showing HIV-1 Gag transfer into CellTracker+ acceptor 
cell after 24h co-culture. HIV-1 Gag (red), Cell Tracker (green), F-actin (grey), DAPI (blue). 
Scale bar, 10μm. (E) Stacked bars showing the percentage of CellTracker+ cells among Gag+ 
cells after 24h co-culture with or without TNTi (20μM). Data in histograms are represented 
as mean ± SD. Each circle within vertical scatter plots represents a single donor. Mean value 
is represented as a dark grey line. Statistical analyses: Two-tailed, paired t-test (A, E), 
Wilcoxon matched-paired signed rank test (B). * p≤0.05; *** p≤0.0005; **** p≤0.0001; ns, 
not significant.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-human CD14 Biolegend Clone M5E2
Anti-human CD16 Biolegend Clone 3G8
Anti-human CD163 Biolegend Clone GHI/61
Anti-human CD184 (CXCR4) Biolegend Clone 12G5
Anti-human CD195 (CCR5) Biolegend Clone J418F1
Anti-human CD274 (B7-H1, PD-L1) Biolegend Clone 29E.2A3
Anti-human CD4 Biolegend Clone RPA-T4
Anti-human CD64 Biolegend Clone 10.1
Anti-human CD86 Biolegend Clone IT2.2
Anti-human HLA-DR Biolegend Clone L243
Anti-human MerTK Biolegend Clone 590H11G1E3
Anti-human STAT3 Cell Signaling Technology Clone D1A5
Anti-human phosphoTyr705-STAT3 Cell Signaling Technology Clone D3A7
Anti-human SAMHD1 Gift from Dr. O Schwartz Institut Pasteur, Paris, France (Laguette et al., 2011)
Anti-human phosphoThr592-SAMHD1 ProSci Cat# 8005
Anti-human IFITM1/2/3 Santa Cruz Biotechnology Clone FL-125
Anti-human C/EBP-β Santa Cruz Biotechnology Clone H-7
Anti-human CUGBP1 Santa Cruz Biotechnology Clone 3B1
Anti-human Actin Sigma-Aldrich Clone 20–33
Anti-human LC3 Sigma-Aldrich Cat# L8918
Anti-human Gag-RD1 Beckman Coulter Clone KC57
Anti-human CD163 Leica/Novocastra Clone 10D6
LEAF purified anti-human IL-10 Biolegend CloneJES3-19F1
LEAF purified rat anti-human IgG2a Biolegend Clone RTK2758
Goat anti-rabbit IgG, AlexaFluor 555 Thermo Fisher Scientific Cat# A-21430
Goat anti-mouse IgG, AlexaFluor 488 Thermo Fisher Scientific Cat# A-10684
Goat anti-Mouse IgG, AlexaFluor 555 Cell Signaling Technology Cat# 4409
Goat anti-rabbit IgG, HRP Thermo Fisher Scientific Cat# 32460
Goat anti-mouse IgG, HRP Thermo Fisher Scientific Cat# 31430
Bacterial and Virus Strains
M. tuberculosis H37Rv N/A N/A
HIV-1 ADA strain Gift from Dr. S Benichou Institut Cochin, Paris, France (Verollet et al., 2015a)
HIV-1 ADA Gag-iGFP strain Gift from Dr P. Benaroch Institut Pasteur, Paris, France (Gaudin et al., 2013)
HIV-1 NLAD8-VSVG Gift from Dr. S Benichou Institut Cochin, Paris, France (Bracq et al., 2017)
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REAGENT or RESOURCE SOURCE IDENTIFIER
HIV-1 ADA (BlaM-Vpr) N/A N/A
Biological Samples
Buffy Coat Etablissement Français du Sang, Toulouse, France N/A
Patients-derived pleural effusions
División de Tisioneumonología at the Instituto 
de Tisioneumonologi’a Vaccarezza-University of 
Buenos Aires, Argentina
N/A
TB patients-derived peripheral blood
División de Tisioneumonología at the Instituto 
de Tisioneumonologi’a Vaccarezza-University of 
Buenos Aires, Argentina
N/A
TB/HIV patients-derived peripheral blood Division de SIDA at the Hospital F.J Muñiz, Buenos Aires, Argentina N/A
Healthy subjects-derived peripheral blood Blood Transfusion Service, Hospital Fernandez, Buenos Aires, Argentina N/A
Histological slides of lung biopsies from rhesus 
macaques Tulane National Primate Research Center N/A
Chemicals, Peptides, and Recombinant Proteins
Human M-CSF Peprotech Cat# 300-25
Stattic Sigma-Aldrich Cat# S7947
TNTi Pharmeks N/A
Cytochalasin D Sigma-Aldrich Cat# 22144-77-0
Maraviroc Sigma-Aldrich Cat# 376348-65-1
Bafilomycin A1 Sigma-Aldrich Cat# 88899-55-2
Critical Commercial Assays
Mouse anti-human CD14 microbeads Miltenyi Biotec Cat# 130-050-201
LS magnetic columns Miltenyi Biotec Cat# 130-042-401
Protein G Agarose, Fast Flow Millipore Cat# 16-266
Renilla Luciferase Assay Promega Cat# E2810
Amersham ECL Prisme Western Blotting Detection 
Reagent GE Healthcare Cat# RPN2232
SuperSignal WestPico Chemiluminescent Substrate Thermo Scientific Cat# 34080
Matrigel BD Bioscience Cat# 356234
IL-10 ELISA set BD Bioscience Cat# 555157
Human CD163 ELISA kit BD Bioscience Cat# DY1607-05
Human Mer ELISA kit BD Bioscience Cat# DY6488
Human TruStain FcX Biolegend Cat#422302
Cell Dissociation Buffer Thermo Fisher Scientific Cat# 13151014
Phalloidin AlexaFluor 488 Thermo Fisher Scientific Cat# A12379
DAPI Sigma Aldrich Cat# D9542
Vybrant® DiO Thermo Fisher Scientific Cat# V22886
CellTracker Red CMPTX Dye Thermo Fisher Scientific Cat# C34552
CellTracker Green CMFDA Dye Thermo Fisher Scientific Cat# C7025
Fluorescence Mounting Medium Agilent Technologies Cat# S302380-2
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REAGENT or RESOURCE SOURCE IDENTIFIER
Prolong anti-fade reagent Thermo Fisher Scientific Cat# P10144
Experimental Models: Cell Lines
TZM-bl cell line NIH AIDS Reagent Program Cat# 8129
Software and Algorithms
ImageJ ImageJ www.imagej.nih.gov/ij
Prism (v5) GraphPad www.graphpad.com
Photoshop CS3 Adobe http://www.adobe.com
Illustrator CS3 Adobe
Huygens Professional Version 16.10 Scientific Volume Imaging https://svi.nl/HuygensProfessional
FACS DIVA BD Bioscience http://www.bdbiosciences.com/
FlowJo 7.6.5 TreeStar https://www.flowjo.com/
FCS Express V3 DeNovo Software http://www.denovosoftware.com
Image Lab Bio-Rad Laboratories http://www.bio-rad.com
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